MedRise Medical News

Ivermectin Mass Drug Administration Cuts Malaria Infections 26% in Kenya: BOHEMIA Trial

Treating entire communities with ivermectin once a month for three months cut malaria infections among children by 26%, according to the BOHEMIA trial published in the New England Journal of Medicine on July 24, 2025.

The drug was not treating malaria. Ivermectin kills mosquitoes that bite people who have taken it, so the idea is to cut transmission across a whole village, including in places where mosquitoes resist the insecticides on bed nets.

What the trial did

  • Where: Kwale County on the coast of Kenya, where malaria is highly endemic and bed net use is high.
  • Who: 84 clusters with 28,932 eligible participants, randomized 1:1.
  • What: ivermectin 400 µg/kg, or albendazole 400 mg as an active control, once a month for 3 months at the start of the short rains.
  • Measured: malaria infection in children 5 to 15 years old, tested monthly for 6 months.

The trial had two primary outcomes, malaria infection in children and adverse events in all eligible participants, analyzed by intention to treat. It was funded by Unitaid and led by Carlos Chaccour of ISGlobal in Barcelona with the Kenya Medical Research Institute.

The result: 2.20 versus 2.66 infections per child-year

Infection incidence was 2.20 per child-year at risk with ivermectin and 2.66 with albendazole, an adjusted incidence rate ratio of 0.74 (95% CI 0.58 to 0.95). Serious adverse events did not differ significantly between groups, and the authors identified no safety concerns.

Why a new tool is needed

The World malaria report 2024 estimated 263 million cases and 597,000 deaths in 2023, about 11 million more cases than in 2022. The trial's authors cite insecticide resistance and changes in mosquito behavior as threats to current control methods.

What it means for students and residents

  • Know the mechanism. This is vector control: protecting a community by killing mosquitoes, not curing an infected patient. Malaria treatment remains artemisinin-based therapy.
  • Read beyond the headline. The effect was measured in one region, over one season, against an active control. Questions about other settings, resistance and cost remain open.
  • Expect patient questions. Ivermectin's history makes it a lightning rod. Be ready to explain exactly what this trial did and did not show. More in MedRise Medical News; sharpen your appraisal skills with MedRise Viva.

An old deworming drug may get a new job, but only as one tool among several.

MedRise Medical News summarizes public announcements and research for education only. It is not medical, legal or immigration advice.

Book a free strategy call

Ten minutes to look at your exam date, your scores and what is getting in the way.